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BACKGROUND: Wilms’ tumour 1 (WT1) gene was discovered as a tumour suppressor gene. Later findings have suggested that
WT1 also can be oncogenic. This complexity is partly explained by the fact that WT1 has a number of target genes.
METHOD: WT1 and its target gene human telomerase reverse transcriptase (hTERT) were analysed in clear cell renal cell carcinoma
(ccRCC). In vitro experiments were performed to examine the functional link between WT1 and hTERT by overexpression of WT1
isoforms in the ccRCC cell line, TK-10.
RESULTS: WT1 demonstrated lower RNA expression in ccRCC compared with renal cortical tissue, whereas hTERT was increased,
showing a negative correlation between WT1 and hTERT (P¼0.005). These findings were experimentally confirmed in vitro. The
WT1 generated effect on hTERT promoter activity seemed complex, as several negative regulators of hTERT transcription, such as
SMAD3, JUN (AP-1) and ETS1, were activated by WT1 overexpression. Downregulation of potential positive hTERT regulators, such
as cMyc, AP-2a, AP-2g, IRF1, NFX1 and GM-CSF, were also observed. Chromatin immunoprecipitation analysis verified WT1 binding to
the hTERT, cMyc and SMAD3 promoters.
CONCLUSION: The collected data strongly indicate multiple pathways for hTERT regulation by WT1 in ccRCC.
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Renal cell carcinoma (RCC) accounts for 3% of adult malignancies
and has a high mortality rate. The three main subtypes of RCC are
clear cell (ccRCC), papillary and chromophobe RCC (Kovacs et al,
1997). Clear cell RCC, representing 75–80% of all RCCs, is
characterised by loss of 3p14.2-p25, duplication of 5q22 and
deletions of chromosomes 6q, 8p, 9p and 14q (Kovacs, 1996).
The Wilms’ tumour 1 (WT1) gene is an important regulator of
cell growth and development with expression in the developing
embryo kidney, adult urogenital system, central nervous system
and in the hematopoietic system (reviewed in Scharnhorst et al
(2001)). In 1990, WT1 was discovered as a tumour suppressor gene
in Wilm’s tumour, a childhood kidney neoplasm (Committe
TNWTS, 1991; Haber et al, 1990). This gene encodes a 49–52kDa
protein with an N-terminal domain involved in RNA/protein
interactions critical for its transcriptional regulatory function (Call
et al, 1990). The C-terminal domain is involved in RNA and
protein interactions and harbours four zinc-fingers and two
nuclear localisation signals, which permit binding to target DNA
sequences (Bruening et al, 1996). By two main alternate splicing
events including splicing of exon 5 (17 amino acids) and exon 9
(three amino acids: lysine, threonine and serine (KTS)), four WT1
protein isoforms are produced designated by the presence
or absence of exon 5/KTS as A ( / ), B (þ/ ), C ( /þ) and
D(þ/þ) (Haber et al, 1991). WT1A ( / ) was demonstrated to
induce morphological changes and promote cell migration and
invasion in ovarian cancer cells (TYK) (Jomgeow et al, 2006). In
osteosarcoma cell lines, induction in programmed cell death was
preferentially mediated by WT1B (þ/ ) through transcriptional
repression of the EGFR gene (Haber et al, 1996). WT1D (þ/þ)
can cause a morphological transition from an epithelial to a more
mesenchymal phenotype (Burwell et al, 2007). As suggested by the
presence of zinc-fingers, WT1 is a potent transcriptional regulator.
A large number of genes coding for growth factors (e.g., TGF-b,
CSF-1), growth factor receptors (e.g., insulin R, IGF-IR, EGFR),
transcription factors (e.g., EGR, WT1, cMyc, Pax2, Dax-1 and Sry)
and other proteins (e.g., ODC, MDR1, Hsp70, p21, Bcl-2) have been
identified as WT1 target genes (reviewed in Ariyaratana and Loeb
(2007); Yang et al (2007)). Also, the WT1 protein has interacting
partners such as p53 and STAT3, which can modulate WT1
transcription functions (Maheswaran et al, 1993; Rong et al, 2006).
Telomerase activation is a key event during immortalisation and
malignant transformation contributing to telomere stabilisation
and extended replicative capacity. Human telomerase reverse
transcriptase (hTERT) is a key component of the telomerase
complex regulated on several levels. The hTERT promoter contains
methylation-accessible CpG islands and its methylation status has
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sbeen associated with hTERT transcriptional repression (Devereux
et al, 1999; Chatagnon et al, 2009). The hTERT core promoter and
sequences upstream contain numerous binding sites for positive
and negative regulators of transcription suggesting a complex
regulation (Takakura et al, 1999). A number of factors can directly
or indirectly regulate the hTERT promoter, including activators
(cMyc, Sp1, ER, HIF-1a, E6 protein, activating enhancer-binding
protein (AP-2) and so on), as well as repressors (WT1, AP-1, p53,
p73, MZF, pRb, E2F and so on) (Cukusic et al, 2008). We have
recently shown that the PI3K pathway is one significant road for
hTERT regulation in ccRCC and that cMyc binding to the hTERT
promoter seemed important for this control (Sitaram et al, 2009).
Oh et al (1999) identified WT1 as a transcriptional repressor
of hTERT in virally transformed human embryonic kidney 293
cells, but the WT1 regulation seemed to be cell type specific. In this
study, we could demonstrate negative associations between WT1
and hTERT and between WT1 and cMyc in clinical ccRCC samples,
data that were verified by cell line transfection experiments. Forced
expression of WT1 in the ccRCC TK-10 cell line reduced hTERT
mRNA levels and telomerase activity by direct WT1 binding to the
hTERT promoter, but also by affecting several genes known to
regulate hTERT transcription. Our results suggest that WT1 can act
as a tumour suppressor in ccRCC via multiple pathways leading to
downregulation of hTERT.
MATERIALS AND METHODS
Tissue samples
We performed the study on a total of 73 ccRCC tumour specimens
and 26 tumour-free renal cortical tissue samples. The tissue
specimens were collected between February 1988 and December
2003 under a protocol approved by the Human Ethics Committee
of the Medical Faculty, Umea ˚ University. Each patient participated
after providing informed consent and during the later years also
with informed and signed consent. All pathology specimens were
reviewed by pathologists according to (Skinner et al, 1971).
Tumour stages were classified according to the TNM classification
2002 (Greene and Sobin, 2002). Follow-up medical records of the
patients were retrospectively updated by surgical urologists and
were used for survival analysis.
RNA extraction and reverse transcription
Total RNA was isolated from snap-frozen tumour specimens and
tumour-free renal cortical tissue using the TRIzol method
(Invitrogen, Stockholm, Sweden). cDNA was prepared by reverse
transcription with the Superscript II Reverse transcriptase kit
according to the manufacturers’ protocol (Invitrogen).
Genome-wide gene expression array
Total RNA (200ng) of each sample was used to produce cRNA
according to the provided protocol of the Illumina Total Prep RNA
Amplification Kit (Ambion Inc., Austin, TX, USA).
A total of 750ng biotinylated cRNA was used for hybridisation
to a human HT12 Illumina Beadchip gene expression array
according to the manufacturers’ protocol (Illumina, San Diego, CA,
USA). The arrays were scanned using the Illumina Bead Array
Reader. For data analysis and normalisation the Illumina
BeadStudio 3.2 software was used. Cell signalling pathway and
network analysis was carried out with the Metacore software
(GeneGo Inc, St Joseph, MI, USA). Samples were normalised by the
quantile algorithm, genes with signal below background levels
were excluded, and differentially expressed genes were identified
by fold change calculations and with the Illumina custom
differential expression algorithm (described in the Illumina Gene
Expression Module user guide) to identify X2-fold and statistically
(Po0.01) differently expressed genes.
Real-time PCR
Quantitative real-time PCR (qRT–PCR) using TaqMan technology
was performed for WT1 expression. Following primers and probe
given, a 119-bp product was used to detect WT1 mRNA levels.
Forward primer: 50-GCTATTCGCAATCAGGGTTACAG-30 (located
on exon 1/2), reverse primer: 50-TGGGATCCTCATGCTTGAATG-30
(located on exon 2); and TaqMan probe: 50-CACACGCCCTCGC
ACCATGC-30 (located on exon 2). The b-actin gene was used for
normalisation of cDNA templates, and sequences of the primes
and probe were previously described (Inoue et al, 1997). The
qRT–PCR reaction was initiated with 2min of incubation at 501C
and then for 10min at 951C, followed by 45 cycles of denaturation
at 951C for 15s and annealing at 601C for 2min. Standard curves
were generated by 10-fold dilutions of plasmid DNA containing the
insert WT1 or b-actin genes.
The expression of hTERT mRNA was measured using the Light
Cycler TeloTAGGG hTERT quantification kit (Roche Diagnostics,
GmbH, Mannheim, Germany). By using a reference standard curve
provided from the qRT–PCR kit, the relative hTERT mRNA
expression (with reference to housekeeping gene, porphobilinogen
deaminase (PBGD)) was calculated as previously described
(Sitaram et al, 2009). For c-Myc, mRNA quantification was
performed by qRT–PCR using SYBR green I technology (Roche
Diagnostics) as previously described (Sitaram et al, 2009). Values
of target gene expression were calculated with template normalised
to house keeping gene PBGD.
SMAD3, ETS1 and AP-2a were analysed by TaqMan assays
according to manufacturer’s protocol with the TaqMan universal
PCR mastermix and run on the ABI Prism 7000 Sequence Detection
System, SMAD3 (Hs00232222_m1), ETS1 (Hs_00901425_m1) and
AP-2a (Hs_01029410_m1) (Applied Biosystems, Foster City, CA,
USA). cDNA from the T-cell lymphoma cell line (CCRF) was used
to generate the standard curves. Collected data were normalised to
b-actin as described above.
Cell culture, plasmid and transient WT1 A ( / ) and
D(þ/þ) transfection
TK-10 cell line with undetectable endogenous WT1 protein was
derived from a primary ccRCC tumour (provided by Dr Xu,
Karolinska Institutet, Stockholm, Sweden) and was used for
transfection experiments. The cells were maintained in 1  DMEM
(Gibco, Stockholm, Sweden) containing 10% fetal calf serum in 5%
CO2 at 371C. pcDNA 3.1(þ) vectors (Invitrogen, Carlsbad, CA,
USA) containing WT1 variant A ( / )o rD( þ/þ) were
constructed as described previously (Jomgeow et al, 2006).
TK-10 cells were transiently transfected with 1mg per well
(1 10
5 cells) of WT1A or WT1D pcDNA 3.1(þ) vectors using
FuGENE 6 (Roche Diagnostic Corp, Indianapolis, IN, USA).
pcDNA 3.1(þ) vector without insert of WT1Ao rWT1D was used
as control. All cells were collected 24 and 48h after transfection for
further analysis.
ChIP analysis
Chromatin immunoprecipitations (ChIPs) were performed using
the Chromatin Immunoprecipitation Kit (Upstate Millipore,
Billerica, MA, USA). Approximately 2–3 10
6 WT1-transfected
TK-10 cells were crosslinked with 1% formaldehyde, followed by
glycine to quench unreacted formaldehyde. Chromatin was
sonicated on ice to shear crosslinked DNA to about 200–1000bp
in length using a Sonifier ultrasonic cell disruptor (Branson,
Danbury, CT, USA) with 12 10s pulses. The sheared chromatin
was resuspended in dilution buffer and 1% of the chromatin was
removed as input, followed by immunoprecipitation using protein
G magnetic beads with 2mg of either anti-WT1 (C-19) antibody
(Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA,) or normal
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srabbit IgG (Cell Signalling Technology Inc, Danvers, MA, USA) at
41C overnight with rotation. After the reversal of crosslinks by
incubation in ChIP elution buffer containing proteinase K at 621C
for 2h, DNA was purified using spin columns.
The PCRs containing 2ml of the immunoprecipitated DNA or
input chromatin, primers and AmpliTaq Gold (Applied Biosystem)
in a 50ml volume were performed with initial denaturation at 951C
for 10min, followed by 35 cycles (951 for 30s, 551C for 30s and
721C for 45s) and a final extension at 721C for 10min. The primer
sequences were as follows for hTERT promoter (NG_009265): P1F
50-TTTGCCCTAGTGGCAGAGAC-30, P1R 50-GCCGGAGGAAATTG
CTTTAT-30; P2F 50-CTACTGCTGGGCTGGAAGTC-30, P2R 50-A
GAAAGGGTGGGAAATGGAG-30; and for SMAD3 promoter
(NG_011990): P1F 50-CCAAGGTGGGAGGAATCAG-30, P1R 50-GA
GTGCAATGGTGCCATCTT-30; P2F 50-CTTCTGGGCTGACTGTGG
AT-30, P2R 50-CGACTAGCCGGTGTCTAAGC-30. The primer
sequences for cMyc promoter were described previously (Han
et al, 2004). PCR products were fractionated on 1% agarose gel,
and ethidium bromide-stained DNA was visualised on Ultraviolet
Transilluminator (Spectroline, Westbury, NY, USA).
Western blot analysis
Total protein were extracted from the tumour samples, normal
renal cortical tissue and transfected TK-10 cells, using CHAPS lysis
buffer (3-((3-cholamidopropyl) dimethyl-ammonio)-1-propane
sulphonate). A total of 10mg of proteins were separated by
10% SDS polyacrylamide gel electrophoresis and transferred to
nitrocellulose membrane (Hybond-ECL, Amersham Biosciences,
Buckinghamshire, UK). Membranes were blocked in TBS contain-
ing 5% dried milk and 0.1% Tween-20 and probed with
monoclonal mouse antibodies against WT1 (1:500; Dako, Glostrup,
Denmark), cMyc (1:1000, Cell Signalling Technology Inc.) and
b-actin antibodies (1:10000, Chemicon International, Temecula,
CA, USA). After a second incubation with peroxidase-conjugated
anti-mouse or anti-rabbit antibodies (1:5000, Dako), proteins
were visualised using an enhanced chemiluminescent detection
system (ECL-advance, Amersham Biosciences).
Immunofluorescence
At 48h after transfection, cells were fixed with 3% formaldehyde
and 2% sucrose in PBSA and then permeabilised with 0.1 M glycine.
Cells were blocked with 2% normal goat serum and 0.4% Triton
X-100 in PBSA for 30min, followed by overnight incubation with
mouse monoclonal WT1 antibody (1:100, Dako). After washing
with 0.2% Triton X-100 in PBSA, cells were probed with secondary
antibody Alexa Flour 488 rabbit anti-mouse IgG (HþL) in 1:500
concentration (Molecular Probes Inc., Eugene, OR, USA), and
DAPI stained for nuclear visualisation. Images were captured using
a NikonEFD3 microscope (Boyce Scientific, Gray Summit, MO,
USA) and Nikon camera (100Eplan (160/0.17) objective; Nikon,
Melville, NY, USA).
Telomerase activity determination
Telomerase activity was evaluated using quantitative telomerase
detection kit (QTD kit, Allied Biotech Inc, Ijamsville, CA, USA).
A total reaction volume of 25ml consisted of 12.5mlo f2   QTD
pre-mix (provided by the kit), 250ng protein CHAPS extract
(supplemented with 1Uml
–1 RNAsin and 1mM DTT) and water.
The qRT–PCR was performed on a 7000 sequence system (Applied
Biosciences). Standard curve generated by TSR control template
allows the calculation of the amount of template with telomeric
repeat created by telomerase using 7000 SDS system software
(Applied Biosystem).
Statistical analysis
Statistical analysis was performed using SPSS (version 15, SPSS
Inc., Chicago, IL, USA) statistical software. Mann–Whitney U-test
was used to compare differences in the gene expressions of two
independent variables. Correlations between two variables were
tested according to Spearman’s correlation test (statistical
significance Pp0.05).
RESULTS
WT1 expression was inversely correlated to hTERT
and cMyc in ccRCC
WT1 mRNA levels were analysed in 73 ccRCC specimens and
26 tumour-free renal cortical tissue samples using qRT–PCR.
Significantly lower WT1 RNA levels were found in the tumour
samples in comparison with renal cortical tissue (Po0.0001), as
shown in Figure 1A, indicating a downregulation of WT1 in
P < 0.0001
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Figure 1 Wilms’ tumour 1 (WT1) expression is negatively related to
human telomerase reverse transcriptase (hTERT) mRNA levels in clear
cell renal cell carcinoma (ccRCC). (A) Significant decrease in WT1 mRNA
expression in ccRCC compared with normal renal cortical tissue.
(B) Western blotting shows decreased WT1 protein expression in four
of five ccRCC tumour samples (T) compared with normal renal cortical
tissue (N). (C) A reverse correlation exists between mRNA expression of
WT1 and hTERT in ccRCC. Samples with low expression levels for both
hTERT (p0.025) and WT1 (p0.25) also showed a similar trend.
WT1 and hTERT in clear cell renal cell carcinoma
RT Sitaram et al
1257
British Journal of Cancer (2010) 103(8), 1255–1262 & 2010 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sccRCC. Immunoblotting for WT1 revealed lower protein levels in
randomly selected tumour samples compared with tumour-free
renal cortical tissues (Figure 1B)
We have previously demonstrated significantly higher mRNA
levels of hTERT and cMyc in ccRCC compared with renal
cortical tissue (Sitaram et al, 2009). In the present ccRCC samples,
negative correlations were found between WT1 and hTERT
(P¼0.005, r¼ 0.328, Figure 1C) and between WT1 and cMyc
(P¼0.05, r¼ 0.246, n¼64, not shown in figures). We could also
demonstrate a tendency towards a negative association between
WT1 and hTERT for a subset of samples with lower expression
levels for both hTERT and WT1 (P¼0.063, Figure 1C).
WT1 expression was not associated with clinical features
WT1 mRNA levels did not differ depending on patient age,
gender, tumour grade or stage (P40.05, for each parameter,
data not shown). No significant difference in survival time was
observed when the ccRCC cases were subdivided into two
subgroups with a cutoff at the median WT1 mRNA level (data
not shown).
Forced expression of WT1 can suppress hTERT and
cMyc mRNA levels
In order to answer whether the WT1 protein can function as a
negative regulator of hTERT and/or cMyc transcription,
we performed transfection experiments using TK-10 cells. High
expression levels of WT1 isoforms A and D were demonstrated at
24 and 48h after transfection (Figure 2A). It has been demon-
strated that nuclear localisation of WT1 is a prerequisite for its
transcriptional regulatory capacity (Ye et al, 1996). Therefore,
immunostaining was performed 48h after transfection verifying
WT1 protein localisation in nuclei (Figure 2B). WT1A and WT1D
overexpression induced a decrease in hTERT and cMyc mRNA
levels as shown in Figures 2C and D. The downregulation of cMyc
was also demonstrated by immunoblotting (Figure 2A). The
repressive effects on cMyc and hTERT varied between experiments.
By plotting the mean expression values for hTERT and cMyc in a
series of separate WT1 transfections, we found a strong correla-
tion, indicating a similar degree of inhibition (Figure 2E). This
gives support for the idea that cMyc is involved in the hTERT
regulation. Furthermore, both WT1A and WT1D transfections
reduced telomerase activity after 24 and 48h (Figure 2F).
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Figure 2 Forced overexpression of Wilms’ tumour 1 (WT1) induces downregulation of human telomerase reverse transcriptase (hTERT) mRNA,
telomerase activity and cMyc expression in TK-10 clear cell renal cell carcinoma (ccRCC) cell line. (A) Western blotting shows increased protein expressions
of WT1 and reduced cMyc protein in WT1-transfected TK-10 cells. (B) TK-10 cells, which were transfected with WT1A or WT1D or pcDNA empty
vector as control, demonstrate predominant nuclear localisation of WT1 protein (green) by immunostaining with anti-WT1. Nuclei were visualised by
4,6-diamidino-2-phenylindole (DAPI) (blue) staining. (C) Decreased cMyc mRNA levels in WT1-overexpressed cells but not in control cells. (D) Decreased
hTERT mRNA levels in WT1-overexpressed cells but not in control cells. (E) A significant correlation between the degree of inhibition for hTERT and cMyc
by forced overexpression of WT1A and WT1D is demonstrated by plotting the mean expression values in a series of separate transfections. (F) Decreased
telomerase activity in WT1-overexpressed cells but not in control cells.
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pathways
Gene expression alterations induced by WT1 transfection in
TK-10 cells were detected using whole genome expression array
analysis and several genes reported to be WT1 targets were found
to be affected (Figure 3). Further analysis was focused on hTERT-
regulating genes identifying an increased expression of several
repressors. Fold changes, based on the array data, in expression
of hTERT transcriptional regulators after WT1 transfection are
summarised in Table 1. Two negative hTERT regulators, SMAD3
and JUN, were significantly upregulated. Moreover, the GM-CSF,
ETS1 and IRF1 genes also with suggested negative effects
on hTERT transcription demonstrated increased expression.
In contrast, AP-2a, AP-2g and NFX1, all with potential
positive effects on hTERT expression, were downregulated. The
altered expression of SMAD3, ETS1 and AP-2a was validated by
qRT–PCR, showing a good correlation with the array data
(Figure 4).
WT1 binds to the hTERT, c-Myc and SMAD3 promoters
To demonstrate that WT1 proteins bind to the promoters of the
hTERT, cMyc and SMAD3 genes, we performed ChIP experiments.
As shown in Figure 5, a single band was observed when chromatins
from WT1-transfected TK-10 cells were immunoprecipitated with
WT1 antibody. This was not observed when rabbit IgG antibody
was used. By ChIP/PCR assay we could demonstrate direct binding
of WT1 to the hTERT, cMyc and SMAD3 promoters.
DISCUSSION
In this study, we describe a functional link between WT1
expression and the transcriptional activity of one of its target
genes, hTERT, in human ccRCC. This link was identified through
(1) an inverse relationship between WT1 and hTERT gene
expression levels in clinical ccRCC samples; (2) direct binding of
WT1A and WT1D to the hTERT promoter; and (3) downregulation
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Figure 3 Altered gene expression of Wilms’ tumour 1 (WT1) target genes and human telomerase reverse transcriptase (hTERT) transcriptional regulators
by WT1 overexpression in TK-10 cells detected using expression array analysis. Network analysis was performed based on array data using the Metacore
GeneGo software. Increased gene expression is indicated by a filled red circle on the upper right corner of each network object, whereas a blue dot indicates
downregulation (X2-fold, Po0.01 compared with control). Gene/protein objects are represented by various shapes and colours depending on
their functional annotations. Colours of the lines indicate inhibition (red) and activation (green), and gray arrows represent unspecified interactions
(e.g., promoter binding).
Table 1 Fold induction in expression of hTERT transcriptional regulator genes in response to forced WT1 expression in TK-10 cells by microarray analysis
Fold change (vs control)
WT1A WT1D
Gene name Synonyms Entrez ID Expected effect on hTERT 24h 48h 24h 48h
CSF2 GM-CSF 1437 Activator/repressor 19.2* 18.7* 15.8* 12.9*
ETS1 ETS1 2113 Activator/repressor 3.5* 2.7* 3.7* 2.5*
IRF1 IRF1 3659 Repressor 1.4 1.9 1.7* 2.6*
JUN AP1 3725 Repressor 12.8* 6.4* 11.9* 5.7*
SMAD3 SMAD3 4088 Repressor 6.3* 3.1* 4.6* 3.5*
NFX1 NFX-123 4799 Activator  2.5*  2.0*  2.1  2.0*
TFAP2A AP-2a 7020 Unspecified  6.8*  8.1*  6.8*  8.0*
TFAP2C AP-2g 7022 Unspecified  3.5*  5.0*  3.6*  5.4*
Abbreviations: hTERT¼human telomerase reverse transcriptase; WT1¼Wilms’ tumour 1. *Statistical significance (Po0.01).
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expression. The collected data indicated that WT1 can control
hTERT expression via multiple pathways and thereby act as a
tumour suppressor in ccRCC.
WT1 is known to be a potent transcriptional regulator of many
downstream targets, and can thus function as a tumour suppressor
or an oncogene depending on cell type and tumour entity. Recent
studies have demonstrated high expression of WT1 in bone and
soft tissue sarcomas, breast cancer and lung cancer (Loeb et al,
2001; Oji et al, 2002; Ueda et al, 2003). Therefore, the WT1 gene has
been proposed as an oncogene in these contexts. In contrast to
these observations, we here found significantly lower WT1 RNA
levels in ccRCC samples compared with tumour-free renal cortical
tissue. Only few studies have previously investigated WT1 in
human RCC. Using northern blot analysis, Campbell et al (1998)
demonstrated aberrant WT1 expression in four out of five RCC
samples and in several RCC-derived cell lines arguing against WT1
being a tumour suppressor in this tumour type. In contrast, later
studies have generated data in accordance with our study. Niu et al
(2005) showed low WT1 transcription levels in ccRCC samples in
comparison with tumour-free kidney tissue. By immunohisto-
chemistry Nakatsuka et al (2006) found WT1 protein in four out of
twelve (33%) ccRCC samples to be compared with 480%
positivity in endometrial and brain tumours. On the basis of these
reports and this study the collected data suggest that WT1 can act
as a tumour suppressor in ccRCC.
The transcriptional activity of the hTERT gene is the net result of
many positively and negatively acting factors. WT1 has been
identified as a cell type-specific hTERT transcriptional repressor,
acting through WT1-binding site in the promoter (Oh et al, 1999).
Our clinical data, showing a negative correlation between WT1
and hTERT RNA levels, support the view that WT1 can suppress
hTERT. In addition, the experimental cell line data further
demonstrated that WT1 overexpression caused hTERT and
telomerase repression. We could also show a direct binding of
WT1 to the hTERT promoter in line with previous observations
(Oh et al, 1999). Bellon and Nicot (2008) recently demonstrated
that IL-2-induced upregulation of hTERT and telomerase activity
in HTLV1-infected cells were due to sequestration of WT1 in the
cytoplasm. In this study, we demonstrated nuclear localisation of
WT1 protein after transfection, indicating that one prerequisite for
its suppressive function was fulfilled.
One known activator of hTERT gene transcription is cMyc
(Wu et al, 1999). In a previous study, we demonstrated a positive
correlation between hTERT and cMyc in ccRCC (Sitaram et al,
2009). Cell line experiments showed that hTERT could be activated
by a novel PTEN regulator, DJ-1, and cMyc seemed necessary for
the upregulation (Sitaram et al, 2009). Studies of WT1 effects on
the cMyc promoter have given divergent results indicating both
stimulatory (Han et al, 2004) and repressive functions (Hewitt
et al, 1995; Han et al, 2004). We observed a strong trend towards a
negative correlation between WT1 and cMyc RNA levels in the
clinical ccRCC samples, and overexpression of WT1 did suppress
cMyc at the transcriptional and protein level. Our observations
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AP-2a (C) by quantitative real-time PCR (qRT–PCR).
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Figure 5 DNA binding of Wilms’ tumour 1 (WT1) protein to the
human telomerase reverse transcriptase (hTERT), cMyc and SMAD3
promoters. Chromatin immunoprecipitation (ChIP)/PCR assay after forced
overexpression of WT1A or WT1D in TK-10 cells as indicated.
The location and size for each PCR product are illustrated on the right.
TSS, transcriptional start site.
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cMyc expression, which may contribute to hTERT expression. The
repressive effects of WT1 on hTERT and cMyc expression seemed
to be parallel in repeated experiments, further indicating that cMyc
acts as a regulator of hTERT in ccRCC.
Microarray analyses have previously been used to identify WT1
target genes (Kim et al, 2007). In this study, we found WT1
induced effects on a number of known targets for WT1, but also on
hTERT transcriptional regulators previously not described as WT1
targets. Among negative hTERT regulators, SMAD3 and JUN were
strongly upregulated by WT1 transfection. ChIP analysis revealed
that WT1 can directly bind to the SMAD3 promoter. Direct
repression of hTERT by SMAD3 via TGF-b signalling has been
reported (Lacerte et al, 2008). JUN was originally thought to
be identical to the transcription factor AP-1. However, it is now
known that AP-1 constitutes a group of dimeric basic region-
leucine zipper proteins that belong to the FOS, MAF and ATF
subfamilies. JUN is the most potent transcriptional activator in this
group of proteins (Hattori et al, 1988). Previous studies have
shown that overexpression of AP-1 can downregulate hTERT
transcription in cancer cells (Takakura et al, 2005). The combina-
tion of c-Fos/c-Jun or c-Fos/JunD strongly suppresses hTERT
promoter activity in transient-expression experiments (Takakura
et al, 2005).
IRF1 has been shown to be important in apoptosis and cell
differentiation (Harada et al, 1993). A previous study demon-
strated that IRF1 is a mediator for interferon-g-induced inhibition
of hTERT expression and telomerase activity in cervical cancer
cells (Lee et al, 2003). In this study we observed about two-fold
increased expression of IRF1 by WT1D, indicating that it might
have a negative effect on hTERT promoter activity. The clinical and
experimental data presented here strongly suggest that WT1
contributes to hTERT inactivation, directly by acting on the
promoter and indirectly via hTERT-negative regulators such as
SMAD3 and JUN.
GM-CSF can regulate hTERT transcription both positively and
negatively, but only in combination with other genes (Mano et al,
2000). GM-CSF was strongly upregulated by WT1 in our analysis,
indicating that it might act as an hTERT repressor. Further, we also
found that WT1 overexpression induced increased ETS1 expres-
sion. Transcriptional activation of ETS1 by WT1 has been reported
in tumour vascularisation via regulation of endothelial cell
proliferation and migration (Wagner et al, 2008). The role of
ETS proteins, especially ETS1 and ETS2, in telomerase regulation
seems to depend on ETS-binding sites in the hTERT promoter and
protein–protein interactions (Dwyer et al, 2007). Xiao et al (2003)
demonstrated an inhibitory as well as an activating effect on
hTERT transcription mediated through different ETS-binding
sites. In this study, increased ETS1 and reduced hTERT expression
by WT1 may suggest a negative role of ETS1 in hTERT
transcriptional regulation in ccRCC.
Two isoforms of NFX1 have been identified, the longer
1120-amino acid isoform as NFX1-123 and the shorter 833-amino
acid isoform as NFX1-91 (Gewin et al, 2004). NFX1-123 was
demonstrated to co-activate the hTERT promoter with cMyc,
whereas NFX1-91 repressed the hTERT promoter (Gewin et al,
2004). Significant reduction of NFX1-123 expression by WT1 was
found in our array analysis, suggesting that it might act as an
hTERT activator in ccRCC. The protein AP-2b has been identified
as a transcriptional activator of the hTERT promoter in human
lung cancer cells (Deng et al, 2007). The family of AP-2 proteins
consists of five different transcriptional factors (a, b, g, d and e),
encoded by separate genes and with different biological functions.
The AP-2-binding site at nucleotides –129 to –121 in the hTERT
promoter is essential for transcriptional regulation during
differentiation of human sarcoma cells (Ma et al, 2003), but the
role of individual AP-2 family members has not been detailed. In
this study AP-2a and AP-2g were downregulated by WT1,
suggesting that WT1 thereby can affect hTERT regulation.
Interestingly, in T-cell cultures we observed that upregulation of
telomerase was associated with decreased expression of GM-CSF,
JUND, ETS1, SMAD3 and increased expression of AP-2a and cMyc
(Degerman et al, 2010). The collected data strengthen the scenario
of hTERT regulation via multiple pathways.
By gene expression array analysis, we found that forced
expression of WT1 had a regulatory function on many known
WT1 target genes. However, the effects on transcription of some
target genes were different from previously published data in other
cellular systems, further supporting the view of cell type specificity
regarding WT1 function. In conclusion, this study strongly
suggests that WT1 can act as a tumour suppressor in ccRCC-
regulating hTERT gene expression via multiple pathways.
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